Patients should be advised to: Start with the lowest dose and increase slowly Eat smaller, more frequent meals Avoid high-fat foods Stay well-hydrated Safety monitoring should include vigilance for: Pancreatitis symptoms (severe persistent abdominal pain) discontinue immediately if suspected Gallbladder disease increased risk with rapid weight loss Hypoglycaemia particularly when combined with insulin or sulphonylureas Renal function deterioration especially with dehydration from gastrointestinal effects Diabetic retinopathy monitor in patients with pre-existing retinopathy, particularly with semaglutide Suspected adverse reactions should be reported via the MHRA Yellow Card scheme
No information provided on this website should be interpreted as a recommendation or endorsement of any specific use outside of lawful research applications
is expanding in-house MIORA clinic Telehealth platform Eden opened its own health club Monarch Athletic Clubs is scaling medically driven gyms NEXT|HEALTH is opening a hub inside Royal Personal Training (RPT) Training With 100+ clubs open and 40 in development, Equinox is uniting hotels, sleep, spa, and fitness
Klow-related collagen changes are measured using fluorescence imaging, qPCR, and tensile testing
J Med Food 9(4):468473 Kuhajda FP, Ronnett GV (2007) Modulation of carnitine palmitoyltransferase-1 for the treatment of obesity
